Naomi F. Rothfield

University of Connecticut — United States

Medicine · Health Sciences

60h-index27.7kcitations156works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Systemic Lupus Erythematosus Research(63), Systemic Sclerosis and Related Diseases(47), Monoclonal and Polyclonal Antibodies Research(29), Inflammatory Myopathies and Dermatomyositis(21), Autoimmune Bullous Skin Diseases(16)

Publications156 total

Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
American Journal of Respiratory and Critical Care Medicine·2017· 120 citedOpen Access
Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up
Journal of Scleroderma and Related Disorders·2017· 35 citedOpen Access
Reply
Pure Amsterdam UMC·2016
Reply
Pure Amsterdam UMC·2016
Reply
Arthritis Care & Research·2015· 1 citedOpen Access
Kidney in Lupus Erythematosus
Contributions to nephrology·2015· 7 cited
Treatment Algorithms in Systemic Lupus Erythematosus
Arthritis Care & Research·2015· 105 citedOpen Access
Exercise during cardiac catheterization distinguishes between pulmonary and left ventricular causes of dyspnea in systemic sclerosis patients
The Clinical Respiratory Journal·2012· 33 cited
Progression of Esophageal Dysmotility in Systemic Sclerosis
The Journal of Rheumatology·2012· 33 citedOpen Access
Osteonecrosis in SLE
Rheumatology International·2011· 6 citedOpen Access
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double‐blind, placebo‐controlled trial
Arthritis & Rheumatism·2009· 152 citedOpen Access
MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trial
Arthritis & Rheumatism·2009· 110 cited
A multicenter, randomized, double‐blind, placebo‐controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late‐phase disease
Arthritis & Rheumatism·2008· 113 citedOpen Access
MQX-503, a novel topical nitroglycerin formulation, improves severity of symptoms associated with Raynaud's phenomenon
Lund University Publications (Lund University)·2008· 6 cited
Safety and tolerability of MQX-503, a novel investigational topical formulation of nitroglycerin for the treatment of Raynaud's phenomenon
Lund University Publications (Lund University)·2008· 1 cited
Comparison of responders and non-responders to MQX-503, a novel investigational topical nitroglycerin formulation, in treatment of scieroderma-related and non-scleroderma-related Raynaud'S phenomenon
Lund University Publications (Lund University)·2008
Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease
American Journal of Respiratory and Critical Care Medicine·2007· 463 citedOpen Access
Impact of oral cyclophosphamide on health‐related quality of life in patients with active scleroderma lung disease: Results from the scleroderma lung study
Arthritis & Rheumatism·2007· 96 citedOpen Access
Outcome measurements in scleroderma: results from a delphi exercise.
PubMed·2007· 72 cited
Lupus erythematosus: systemic and cutaneous manifestations
Clinics in Dermatology·2006· 193 cited
page 1 of 8Next →

Frequent Co-authors

Maureen D. Mayes(14), Philip J. Clements(10), James R. Seibold(10), Robert W. Simms(10), Fredrick M. Wigley(10), Virginia Steen(10), William C. Earnshaw(10), Richard M. Silver(7), Vivien Hsu(7), Barbara White(7), Dinesh Khanna(7), Peter A. Merkel(7), Joseph H. Korn(7), Daniel E. Fürst(7), Donald P. Tashkin(6), Michael D. Roth(6), Daniel E. Furst(6), John Varga(6), Barri J. Fessler(6), Mary Ellen Csuka(6)